Compare RUMBW & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUMBW | WGSWW |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | United States |
| Employees | 135 | 1300 |
| Industry | Computer Software: Prepackaged Software | Retail: Computer Software & Peripheral Equipment |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | RUMBW | WGSWW |
|---|---|---|
| Price | $1.18 | $0.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.7K | ★ 61.3K |
| Earning Date | 03-28-2025 | 02-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $85,651,775.00 | ★ $305,450,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 6.36 | ★ 50.79 |
| 52 Week Low | $0.90 | $0.01 |
| 52 Week High | $4.25 | $0.29 |
| Indicator | RUMBW | WGSWW |
|---|---|---|
| Relative Strength Index (RSI) | 35.32 | 34.65 |
| Support Level | N/A | $0.01 |
| Resistance Level | $2.81 | $0.02 |
| Average True Range (ATR) | 0.19 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 39.02 | 10.48 |
Rumble Inc is a free-to-use video-sharing platform where users can watch, share, like, comment, and upload their own videos. Users can subscribe to channels to stay in touch with recent creator content and access video-on-demand uploaded, and live content streamed, by creators. Geographically, it generates a majority of its revenue from the United States.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.